INDIAN-IMMIGRATION
8.6.2022 10:02:10 CEST | Business Wire | Press release
India has recently become a popular tourist destination for travelers thanks to the breathtaking sceneries it has to offer. Besides adventure travel and cultural tours, wellness tourism in India has emerged as a significant and rapidly expanding tourism segment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220608005070/en/
The growth of wellness tourism in India
In 2020, India ranked 12th in the top 20 largest wellness tourism markets in the world, with more than 48.2 million wellness trips. Making use of this travelers' interest, India offers plenty of wellness retreats and resorts for tourists as well as advantageous conditions to get Indian visas.
Many travelers may be confused about the difference between wellness tourism and medical tourism . Medical tourism is about traveling to a different place for specific medical treatments while wellness tourism is associated with the pursuit of maintaining or enhancing travelers’ wellbeing.
Especially, more people are choosing health and wellness tourism in India to recharge their batteries and refresh themselves post pandemic.
Lauren Jane, an American traveler who had a wellness vacation in Ananda in the Himalayas Resort, India, says: “The activities here help me re-balance and relieve stress after the pandemic, while the healthy organic cuisine maintains my health during the trip. I will come back to experience more wellness tourism destinations in India.”
Typical types of wellness tourism in India and corresponding entry documents
India focuses on promoting wellness tourism in 03 key sectors: Meditation, yoga, and massage therapies.
One of the most popular activities on a wellness trip in India is meditation. Travelers will participate in meditation activities in a natural space of plants, water, and clouds. Meditation is a good way for tourists to reset their bodies, and enjoy the moments of relaxation in their souls.
Known as the birthplace of yoga, India promotes the construction of wellness retreats suitable for yoga practices. Most of the retreats are settled close to nature, surrounded by the lush green forests, providing tourists with quiet spaces for doing yoga.
Ayurvedic massage is unique in many wellness retreats in India, bringing relaxing and soothing experiences for tourists. This massage therapy uses oils, herbs, and natural products to help tourists relieve emotional stress, rejuvenate their mind and soul.
“To experience wellness tours in India, travelers just need to prepare a valid passport to apply for an Indian visa, ” said Mrs. Kim, Relationship Manager in Indian Immigration Services.
Useful tips for tourists from Indian Immigration Service Experts
For a pleasant trip to India, travelers should get a visa beforehand. “To choose a reliable partner for making an eVisa, travelers need to consider factors including the fees, processing time, and professionalism of the staff,” Mrs. Kim also said.
Instead of visiting the embassy to apply for a India visa, foreign travelers can obtain an eVisa on the Indian Immigration Services website. As an applicant, travelers need to meet the visa requirements to be granted an Indian eVisa for tourists.
India Immigration Services makes it easier for travelers to apply for an Indian visa online with reasonable Indian eVisa fees. We assisted more than 25,000 customers globally in making eVisas to India. In addition, we also offer Travel Insurance in order to help our customers cover the cost of medical treatments during the trip.
No more complicated process to get a Visa to enter India, travelers now can expect to have a memorable wellness trip in this fascinating country with India Immigration Services.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220608005070/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom